561 related articles for article (PubMed ID: 34562844)
1. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.
Ghasemiyeh P; Mohammadi-Samani S; Firouzabadi N; Dehshahri A; Vazin A
Int Immunopharmacol; 2021 Nov; 100():108162. PubMed ID: 34562844
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
3. Lessons we learned during the past four challenging years in the COVID-19 era: pharmacotherapy, long COVID complications, and vaccine development.
Ghasemiyeh P; Mohammadi-Samani S
Virol J; 2024 Apr; 21(1):98. PubMed ID: 38671455
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
7. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
8. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
Motamedi H; Ari MM; Dashtbin S; Fathollahi M; Hossainpour H; Alvandi A; Moradi J; Abiri R
Int Immunopharmacol; 2021 Jul; 96():107763. PubMed ID: 34162141
[TBL] [Abstract][Full Text] [Related]
9. Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2.
Firouzabadi N; Ghasemiyeh P; Moradishooli F; Mohammadi-Samani S
Int Immunopharmacol; 2023 Apr; 117():109968. PubMed ID: 37012880
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccines: concerns beyond protective efficacy and safety.
Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
[TBL] [Abstract][Full Text] [Related]
12. Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.
Kumar S; Çalışkan DM; Janowski J; Faist A; Conrad BCG; Lange J; Ludwig S; Brunotte L
Front Immunol; 2021; 12():752227. PubMed ID: 34659259
[TBL] [Abstract][Full Text] [Related]
13. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
14. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
Hodgson SH; Mansatta K; Mallett G; Harris V; Emary KRW; Pollard AJ
Lancet Infect Dis; 2021 Feb; 21(2):e26-e35. PubMed ID: 33125914
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.
Liu Q; Qin C; Liu M; Liu J
Infect Dis Poverty; 2021 Nov; 10(1):132. PubMed ID: 34776011
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.
Sharma D
Expert Rev Vaccines; 2021 Sep; 20(9):1051-1057. PubMed ID: 34313516
[TBL] [Abstract][Full Text] [Related]
17. Highlight of severe acute respiratory syndrome coronavirus-2 vaccine development against COVID-19 pandemic.
Liu CH; Huang HY; Tu YF; Lai WY; Wang CL; Sun JR; Chien Y; Lin TW; Lin YY; Chien CS; Huang CH; Chen YM; Huang PI; Wang FD; Yang YP
J Chin Med Assoc; 2021 Jan; 84(1):9-13. PubMed ID: 33186212
[TBL] [Abstract][Full Text] [Related]
18. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
19. Current advances in the development of SARS-CoV-2 vaccines.
Awadasseid A; Wu Y; Tanaka Y; Zhang W
Int J Biol Sci; 2021; 17(1):8-19. PubMed ID: 33390829
[TBL] [Abstract][Full Text] [Related]
20. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
